(Q35170212)

English

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

6 August 2017

Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression (English)

1 reference

Europe PubMed Central

6 August 2017

phase II clinical trial

0 references

chemoradiotherapy

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

pancreatic adenocarcinoma

1 reference

based on heuristic

inferred from title

11

object named as

Prajnan Das

1 reference

Europe PubMed Central

6 August 2017

James Lewis Abbruzzese

13

object named as

James L Abbruzzese

1 reference

Europe PubMed Central

6 August 2017

10

object named as

Jason B Fleming

1 reference

Europe PubMed Central

6 August 2017

author name string

Christopher H Crane

1

1 reference

Europe PubMed Central

6 August 2017

Gauri R Varadhachary

2

1 reference

Europe PubMed Central

6 August 2017

John S Yordy

3

1 reference

Europe PubMed Central

6 August 2017

Gregg A Staerkel

4

1 reference

Europe PubMed Central

6 August 2017

Milind M Javle

5

1 reference

Europe PubMed Central

6 August 2017

Howard Safran

6

1 reference

Europe PubMed Central

6 August 2017

Waqar Haque

7

1 reference

Europe PubMed Central

6 August 2017

Bridgett D Hobbs

8

1 reference

Europe PubMed Central

6 August 2017

Sunil Krishnan

9

1 reference

Europe PubMed Central

6 August 2017

Jeffrey E Lee

12

1 reference

Europe PubMed Central

6 August 2017

Robert A Wolff

14

1 reference

Europe PubMed Central

6 August 2017

language of work or name

0 references

publication date

27 June 2011

1 reference

Europe PubMed Central

6 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

6 August 2017

29

1 reference

Europe PubMed Central

6 August 2017

22

1 reference

Europe PubMed Central

6 August 2017

3037-3043

1 reference

Europe PubMed Central

6 August 2017

Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

Cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line metastatic pancreatic cancer: a multicentre phase II study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

Epidermal growth factor receptor and tumor response to radiation: in vivo preclinical studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

Reporting results of cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

13 July 2018

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

27 September 2018

Impact of Chemoradiotherapy After Disease Control With Chemotherapy in Locally Advanced Pancreatic Adenocarcinoma in GERCOR Phase II and III Studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3157965

16 November 2018

Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas

1 reference

https://pubmed.ncbi.nlm.nih.gov/21709185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21709185

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2010.33.8038

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

1 reference

Europe PubMed Central

6 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35170212&oldid=1980028544"